Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: Randomized, double-blind study in malaria-naïve adults

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 8, 2014, Pages 2211-2219

  Leroux Roels, Geert ^a   Leroux Roels, Isabel ^a   Clement, Frédéric ^a   Ofori Anyinam, Opokua ^b   Lievens, Marc ^b   Jongert, Erik ^b   Moris, Philippe ^b   Ballou, W Ripley ^b   Cohen, Joe ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GSK   (Belgium)

Author keywords

Adjuvant; AS01; AS02; Cell mediated immunity; Humoral immunity; Malaria; Vaccine

Indexed keywords

ADJUVANT SYSTEM AS 01; ADJUVANT SYSTEM AS 02; CIRCUMSPOROZOITE PROTEIN; CIRCUMSPOROZOITE PROTEIN ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; PLACEBO; PROTEIN ANTIBODY; SODIUM CHLORIDE; UNCLASSIFIED DRUG; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; CYTOKINE; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT VACCINE; RTS,S-AS01 VACCINE; RTS,S-AS02A VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTHRALGIA; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILL; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLOW CYTOMETRY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MALARIA; MALE; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SORE THROAT; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; ANTIBODY AFFINITY; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; MONONUCLEAR CELL; NORMAL HUMAN; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; ANTIBODY AFFINITY; CYTOKINES; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLOW CYTOMETRY; HEALTHY VOLUNTEERS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALARIA VACCINES; MALE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; TREATMENT OUTCOME; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84908373235     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29375     Document Type: Article

References (30)

1. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin 2010; 6:90-6; PMID:19806009; http://dx.doi.org/10.4161/hv.6.1.9677
2. WHO Malaria Policy Advisory Committee and Secretariat. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. Malar J 2012; 11:424; PMID:23253143; http://dx.doi.org/10.1186/1475-2875-11-424
3. Regules JA, Cummings JF, Ockenhouse CF. The RTS,S vaccine candidate for malaria. Expert Rev Vaccines 2011; 10:589-99; PMID:21604980; http://dx.doi.org/10.1586/erv.11.57
4. Garc¸on N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011; 10:471-86; PMID:21506645; http://dx.doi.org/10.1586/erv.11.29
5. White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, Ockenhouse CF, Ghani AC. The relationship between RTS,S vaccine-induced antibodies, CD4+ T cell responses and protection against Plasmodium falciparum infection. PLoS One 2013; 8:e61395; PMID:23613845; http://dx.doi.org/10.1371/journal.pone.0061395
6. Ndungu FM, Mwacharo J, Kimani D, Kai O, Moris P, Jongert E, Vekemans J, Olotu A, Bejon P. A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E. PLoS One 2012; 7:e52870; PMID:23300801; http://dx.doi.org/10.1371/journal.pone.0052870
7. Lumsden JM, Schwenk RJ, Rein LE, Moris P, Janssens M, Ofori-Anyinam O, Cohen J, Kester KE, Heppner DG, Krzych U. Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-α producing effector and central memory CD4 T cells. PLoS One 2011; 6:e20775; PMID:21779319; http://dx.doi.org/10.1371/journal.pone.0020775
8. Ansong D, Asante KP, Vekemans J, Owusu SK, Owusu R, Brobby NA, Dosoo D, Osei-Akoto A, Osei-Kwakye K, Asafo-Adjei E, et al. T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS One 2011; 6:e18891; PMID:21556142; http://dx.doi.org/10.1371/journal.pone.0018891
9. Agnandji ST, Fendel R, Mestré M, Janssens M, Vekemans J, Held J, Gnansounou F, Haertle S, von Glasenapp I, Oyakhirome S, et al. Induction of Plasmodium falciparum -specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D). PLoS One 2011; 6:e18559; PMID:21494604; http://dx.doi.org/10.1371/journal.pone.0018559
10. Olotu A, Moris P, Mwacharo J, Vekemans J, Kimani D, Janssens M, Kai O, Jongert E, Lievens M, Leach A, et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. PLoS One 2011; 6:e25786; PMID:21998698; http://dx.doi.org/10.1371/journal.pone.0025786
11. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, et al.; RTS,S Vaccine Evaluation Group. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009; 200:337-46; PMID:19569965; http://dx.doi.org/10.1086/600120
12. Polhemus ME, Remich SA, Ogutu BR, Waitumbi JN, Otieno L, Apollo S, Cummings JF, Kester KE, Ockenhouse CF, Stewart A, et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One 2009; 4:e6465; PMID:19649245; http://dx.doi.org/10.1371/journal.pone.0006465
13. Owusu-Agyei S, Ansong D, Asante K, Kwarteng Owusu S, Owusu R, Wireko Brobby NA, Dosoo D, Osei Akoto A, Osei-Kwakye K, Adjei EA, et al. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS One 2009; 4:e7302; PMID:19806184; http://dx.doi.org/10.1371/journal.pone.0007302
14. Lell B, Agnandji S, von Glasenapp I, Haertle S, Oyakhiromen S, Issifou S, Vekemans J, Leach A, Lievens M, Dubois MC, et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS One 2009; 4:e7611; PMID:19859560; http://dx.doi.org/10.1371/journal.pone.0007611
15. RTS,S Clinical Trials Partnership; Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmüller B, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365:1863-75; PMID:22007715; http://dx.doi.org/10.1056/NEJMoa1102287
16. RTS,S Clinical Trials Partnership; Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmüller B, Issifou S, Kremsner PG, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367:2284-95; PMID:23136909; http://dx.doi.org/10.1056/NEJMoa1208394
17. Committee for Medicinal Products for Human Use (CHMP). Guideline on adjuvants in vaccines for human use. The European Medicines Agency; 2005. Report No.: EMEA/CHMP/VEG/134716/2004.
18. Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol 2009; 21:265-72; PMID:19524453; http://dx.doi.org/10.1016/j.smim.2009.05.010
19. Cerutti A, Puga I, Cols M. Innate control of B cell responses. Trends Immunol 2011; 32:202-11; PMID:21419699; http://dx.doi.org/10.1016/j.it.2011.02.004
20. Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 2011; 23:598-604; PMID:21889323; http://dx.doi.org/10.1016/j.coi.2011.08.003
21. Reece WH, Pinder M, Gothard PK, Milligan P, Bojang K, Doherty T, Plebanski M, Akinwunmi P, Everaere S, Watkins KR, et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 2004; 10:406-10; PMID:15034567; http://dx.doi.org/10.1038/nm1009
22. Pinder M, Reece WH, Plebanski M, Akinwunmi P, Flanagan KL, Lee EA, Doherty T, Milligan P, Jaye A, Tornieporth N, et al. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia. Clin Exp Immunol 2004; 135:286-93; PMID:14738458; http://dx.doi.org/10.1111/j.1365-2249.2004.02371.x
23. Barbosa A, Naniche D, Aponte JJ, Manaca MN, Mandomando I, Aide P, Sacarlal J, Renom M, Lafuente S, Ballou WR, et al. Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique. Infect Immun 2009; 77:4502-9; PMID:19651872; http://dx.doi.org/10.1128/IAI.00442-09
24. Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, Glenn G, Ockenhouse CF, Garcon N, Schwenk R, et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 1998; 178:1139-44; PMID:9806046; http://dx.doi.org/10.1086/515657
25. Lalvani A, Moris P, Voss G, Pathan AA, Kester KE, Brookes R, Lee E, Koutsoukos M, Plebanski M, Delchambre M, et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 1999; 180:1656-64; PMID:10515829; http://dx.doi.org/10.1086/315074
26. Macdonald RA, Hosking CS, Jones CL. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J Immunol Methods 1988; 106:191-4; PMID:3339255; http://dx.doi.org/10.1016/0022-1759(88)90196-2
27. Garc¸on N, Leroux-Roels G, Cheng W-F. Vaccine adjuvants. In: Garc¸on N, Stern PL, Cunningham AL, Stanberry LR, editors. Understanding Modern Vaccines: Perspectives in Vaccinology. Elsevier B.V.; 2011. 89-113.
28. Clement F, Dewar V, Van Braeckel E, Desombere I, Dewerchin M, Swysen C, Demoitié MA, Jongert E, Cohen J, Leroux-Roels G, et al. Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum. Malar J 2012; 11:384; PMID:23173602; http://dx.doi.org/10.1186/1475-2875-11-384
29. Leroux-Roels I, Leroux-Roels G, Ofori-Anyinam O, Moris P, De Kock E, Clement F, Dubois MC, Koutsoukos M, Demoitié MA, Cohen J, et al. Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults. Clin Vaccine Immunol 2010; 17:1763-71; PMID:20861328; http://dx.doi.org/10.1128/CVI.00133-10
30. Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, Leroux-Roels GG, Van Mechelen M. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443-54; PMID:21174144; http://dx.doi.org/10.1007/s10875-010-9490-6